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Abstract
Skeletal myopathy is a hallmark of heart failure (HF) and has been associated with a poor prognosis. HF and other chronic degenerative dis-
eases share a common feature of a stressed system: sympathetic hyperactivity. Although beneficial acutely, chronic sympathetic hyperactivity
is one of the main triggers of skeletal myopathy in HF. Considering that b2-adrenoceptors mediate the activity of sympathetic nervous system in
skeletal muscle, we presently evaluated the contribution of b2-adrenoceptors for the morphofunctional alterations in skeletal muscle and also
for exercise intolerance induced by HF. Male WT and b2-adrenoceptor knockout mice on a FVB genetic background (b2KO) were submitted to
myocardial infarction (MI) or SHAM surgery. Ninety days after MI both WT and b2KO mice presented to cardiac dysfunction and remodelling
accompanied by significantly increased norepinephrine and epinephrine plasma levels, exercise intolerance, changes towards more glycolytic
fibres and vascular rarefaction in plantaris muscle. However, b2KO MI mice displayed more pronounced exercise intolerance and skeletal myo-
pathy when compared to WT MI mice. Skeletal muscle atrophy of infarcted b2KO mice was paralleled by reduced levels of phosphorylated Akt
at Ser 473 while increased levels of proteins related with the ubiquitin-–proteasome system, and increased 26S proteasome activity. Taken
together, our results suggest that lack of b2-adrenoceptors worsen and/or anticipate the skeletal myopathy observed in HF.
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Introduction
Heart failure (HF) is a complex syndrome involving multiple sys-
tems and neurohumoral compensatory mechanisms accompanied
by high morbidity and mortality, and it is characterized by clinical
signs, such as fatigue, dyspnoea and exercise intolerance [1, 2].
Although HF is a syndrome of cardiac origin, it leads to skeletal
muscle atrophy, a co-morbidity that is associated with poor
prognosis [3–5].
Short-term increases in sympathetic activity lead to increases in
skeletal muscle mass. Conversely, chronic sympathetic hyperactivity
is detrimental, contributing to muscle wasting in HF, as demonstrated
previously [6]. In fact, sympathetic hyperactivity in HF could decrease
the density and sensitivity of skeletal muscle b2-adrenoceptor (b2-
AR), reducing anabolic and anti-catabolic stimuli promoted by these
receptors on skeletal muscle fibres.
It is known that b2-AR subtype is highly prevalent (~90%) in skel-
etal muscle and plays a key role in regulating skeletal muscle mass in
both anabolic and catabolic conditions [7]. The activation of these
receptors leads to increased protein synthesis and inhibition of pro-
tein degradation pathways [8, 9]. Furthermore, we have shown
recently that b2-ARs are also involved in endurance capacity [10].
However, the involvement of b2-AR signalling in skeletal muscle mor-
phology and functional capacity changes observed in HF is not known
yet. Taking into consideration that b2-ARs mediate the activity of
sympathetic nervous system in skeletal muscle and that sympathetic
hyperactivity is one of the main components involved in HF-induced
skeletal myopathy [11], one would suggest that chronic activation of
b2-AR is associated with skeletal muscle morphofunctional alterations
in HF.
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In the present study, we tested the hypothesis that lack of b2-
ARs would aggravate skeletal myopathy and exercise intolerance in
myocardial infarction (MI)-induced HF mice. For doing that, we
have submitted b2-adrenoceptors knockout mice (b2KO) in FVB
genetic background to MI or SHAM surgery to evaluate the contri-
bution of b2-ARs on morphofunctional alterations in skeletal mus-
cle and also on exercise intolerance induced by HF. The key
findings of the present study are that MI-induced cardiac dysfunc-
tion and remodelling in both WT and b2KO mice, which was
accompanied by significantly increased norepinephrine and epi-
nephrine plasma levels, exercise intolerance, changes in muscle
fibre type and vascular rarefaction in plantaris muscles. However,
infarcted b2KO mice displayed a higher decrease in exercise toler-
ance and more severe skeletal myopathy associated with reduced
levels of phosphorylated Akt at ser473, increased levels of proteins
related with the ubiquitin–proteasome system (UPS), and increased
26S proteasome activity.
Materials and methods
Animal model and experimental design
Four-month-old male FVB mouse strain lacking b2-adrenoceptor (b2KO)
[12] and their age-matched wild-type controls (WT) were randomly
assigned into MI or fictitious surgery (SHAM). Mice were deeply anaes-
thetized with ketamine (80 mg/kg, ip) and xylazine (6 mg/kg, ip), fol-
lowed by left thoracotomy and ligation of the left anterior descending
(LAD) coronary artery. SHAM operated animals underwent the same
surgical procedures, except for LAD ligation. Three months after surgi-
cal procedures, mice were submitted to echocardiographical assess-
ment, exercise testing and ambulation test for assessment of functional
capacity, as described below.
Wild-type SHAM group refers to FVB mice, fictitiously operated con-
trol group, WT MI group refers to three-month post-MI FVB mice, b2KO
SHAM group refers to fictitiously operated b2KO mice, and b2KO MI
group refers to three-month post-MI b2KO mice. The animals were
maintained at School of Physical Education and Sport of University of
S~ao Paulo, in a 12:12-h dark–light cycle and a temperature-controlled
environment (22°C) with free access to standard laboratory chow (Nuvi-
tal Nutrients, Curitiba, Brazil) and tap water. All procedures were per-
formed in accordance with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health, Bethesda, MD, USA)
and with ethical principles in animal research adopted by the Brazilian
College of Animal Experimentation (www.cobea.org.br). In addition, this
study was approved by University of S~ao Paulo-EEFE Ethical Committee
(CEP no. 2008/53).
Echocardiographical evaluation
Non-invasive cardiac function was assessed by two-dimensional guided
M-mode echocardiography, in ketamine- (80 mg/kg) and xylazine
(6 mg/kg)-anaesthetized WT and b2KO mice. Briefly, mice were posi-
tioned in the supine position and an ultrasound transmission gel was
applied to the precordium. Transthoracic echocardiography was per-
formed using Sequoia 512 echocardiography machine (Acuson, Moun-
tain View, CA, USA) equipped with a 14-MHz linear transducer. Heart
rate was kept similar in all groups studied during the evaluation to
avoid artifactual changes in left ventricle fractional shortening (FS). Left
ventricle systolic function was estimated by FS as follows: FS
(%) = [(LVEDD  LVESD)/LVEDD] 9 100, where, LVEDD means left
ventricular end-diastolic diameter, and LVESD means left ventricular
end-systolic diameter.
Graded treadmill exercise test
Exercise capacity, estimated by total distance run, correlates with skele-
tal muscle work capacity. Exercise capacity was evaluated using a
graded treadmill exercise protocol for mice as previously described
[13]. Briefly, after being adapted to treadmill exercises over a week
(10 min. of exercise per session), mice were placed in the treadmill
lane and allowed to acclimatize for at least 30 min. Intensity of exercise
was increased by 3 m/min. (6–45 m/min.) every 3 min. at 0% grade,
with no electric shock, until exhaustion. Exhaustion was defined as the
moment when animals were unable to keep in pace with the treadmill
for up to 1 min.
Skeletal muscle functional assessment
Mice were submitted to the ambulation test, which determined the
mean step length, measured in hind foot ink prints while mice ran freely
in a corridor (length 50 cm; width 8 cm; height of lateral walls 20 cm)
[14]. The mice were subjected to three successive trials, and the perfor-
mance of each animal was measured as its best individual performance
over the three trials [15].
Catecholamine measurements
Plasma norepinephrine and epinephrine were measured by HPLC using
ion-pair reverse-phase chromatography coupled with electrochemical
detection (0.5 V), as previously described [16].
Plantaris fibre typing and cross-sectional area
Forty-eight hours after the graded treadmill exercise test, mice were
killed and plantaris muscles were harvested, immediately frozen in melt-
ing isopentane and stored in liquid nitrogen. Frozen muscles were cut
into 10-lm cross-sections from the proximal to distal region using a
cryostat (Micron HM505E; Zeiss, Walldorf, Germany). Muscle sections
were then incubated for myofribrillar ATPase activity after alkali (myosin
ATPase, pH 10.3) or acid (myosin ATPase, pH 4.6) pre-incubation as
previously described [17]. The myosin ATPase reaction was used to
identify the muscle fibre type. Type I fibres reacted deeply after acid
pre-incubation at pH 4.6 and lightly after formaldehyde pre-treatment
and alkali pre-incubation at pH 10.3. The inverse occurred with type II
muscle fibres. Fibre typing and fibre cross-sectional area (CSA) were
evaluated in whole plantaris muscle (~500 and 300 fibres) at 9200
magnification and further analysed on a digitizing unit connected to a
computer (Image-Pro Plus; Media Cybernetics, Silver Spring, MD, USA).
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The total number of each fibre type was counted to calculate the
numerical fibre type composition (I, IIA and IIB). The CSA of each fibre
type was measured for further calculation of average fibre CSA. All
analyses were conducted by a single observer (V.A.V.) blinded to
mouse’s identity.
Capillary-to-fibre ratio
Capillary-to-fibre ratio of plantaris muscle was evaluated after myofibril-
lar ATPase histochemistry reaction at pH 10.3 as previously described
[18]. Briefly, capillary-to-fibre ratio was quantified by a 10 9 10 grid
optically superimposed on each of five non-overlapping fields at 9400
magnification, distributed in a random manner using a computer-
assisted morphometric system (Quantimet 500; Leica, Cambridge, UK).
For calculating capillary-to-fibre ratio, the total number of capillaries
was divided by the total number of fibres counted in the same field for
whole plantaris (~500 fibres). Only vessels with a diameter <10 lm
were counted, which would largely comprise capillaries but might also
include terminal arterioles or venules. All analyses were conducted by a
single observer (V.A.V.) blinded to mouse’s identity.
Skeletal muscle protein expression
Immunoblots of WT SHAM, WT MI, b2KO SHAM and b2KO MI plantaris
muscle homogenates were performed as described [19]. Briefly, liquid
nitrogen-frozen muscles were homogenized in a buffer containing Man-
nitol 210 mM, Sucrose 70 mM, MOPS 5 mM, EDTA 1 mM, 0.1%Triton
9100, pH 7.4 and protease inhibitor cocktail (1:100; Sigma-Aldrich, St.
Louis, MO, USA). Samples were loaded and subjected to SDS-PAGE
(8%, 10% and 12% gel percentages, depending on the protein). After
electrophoresis, proteins were electrotransferred to nitrocellulose mem-
brane (Amersham Biosciences, Piscataway, NJ, USA). Equal loading of
samples (25 lg) and even transfer efficiency were monitored with the
use of 0.5% Ponceau S staining of the blotted membrane. The blotted
membrane was then incubated in a blocking buffer (5% bovine serum
albumin, 10 mM TrisHCl, pH 7.6, 150 mM NaCl and 0.1% Tween 20)
for 2 hrs at room temperature and then incubated with a specific anti-
body overnight at 4°C. Antibodies to Protein Kinase B phosphorylated at
ser473 (p-Akt ser473; Cell Signaling Technology, Beverly, MA, USA),
Protein Kinase B (Akt1; abcam, Cambridge, UK), Eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1; Cell Signaling Technol-
ogy), Eukaryotic translation initiation factor 4E-binding protein 1 phos-
phorylated at thr70 (p-4E-BP1 thr70; Cell Signaling Technology),
Eukaryotic translation initiation factor 4E-binding protein 1 phosphory-
lated at thr37/46 (p-4E-BP1 thr37/46; Cell Signaling Technology), Fork-
head Box O3 (FoxO3a; Cell Signaling Technology), Forkhead Box O3
phosphorylated at ser253 (p-FoxO3a ser253; Cell Signaling Technology),
F-box protein 32 (Atrogin-1, Anti-Fbx-32; abcam), Muscle RING-finger
protein-1 (MuRF-1; Santa Cruz Biotechnology, Dallas, TX, USA), Protein
ubiquitination (Ubiquitin Antibody; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Binding of the primary antibody was detected with the
use of peroxidase-conjugated secondary antibodies (anti-rabbit IgG e
antimouse IgG; Cell Signaling Technology, for 1.5 hr at room tempera-
ture) and detection was performed in a digitalizing unit (ChemiDoc; Bio-
Rad, Hercules, CA, USA) after incubation with luminol and hydrogen
peroxide as HRP substrate. Quantification analysis of blots was
performed using ImageJ software (U.S. National Institutes of Health,
Bethesda, MD, USA). Targeted bands were normalized to Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH; Cell Signaling Technology).
Skeletal muscle protein ubiquitination was analysed in the broadest
molecular weight range as possible and results were corrected to Pon-
ceau red staining (0.5%, w:v) of the membrane. Data are presented as
percentage of SHAM group (arbitrarily set as 100%). Representative
blots are provided along with the data.
Proteasomal activity
Muscles were homogenized in a buffer containing Mannitol 210 mM,
Sucrose 70 mM, MOPS 5 mM, EDTA 1 mM, 0.1% Triton 9100, pH
7.4, in absence of protease inhibitors and centrifuged for 15 min. at
12,000 9 g and 4°C, pellet was discarded and supernatant (soluble
proteins) was used for the assay. 26S Proteasome activity was mea-
sured as the cleavage rate of a synthetic fluorescent peptide (Suc-
LLVY-AMC, product #P802-0005 from Enzo Life Sciences, Farmingdale,
NY, USA), a specific substrate of proteasome chymotrypsin catalytic
site. Reaction mixture contained 25 mM Tris (pH 7.4), 5 mM MgCl2,
25 lM ATP, 25 lM LLVY-AMC and the sample (25 lg of soluble pro-
teins). Fluorescent product formation was followed up for 90 min. (440
and 350 nm were emission and excitation wavelengths respectively) at
37°C in the presence or absence of epoxomycin (20 lM), a highly spe-
cific inhibitor of chymotrypsin-like proteasome activity, and the differ-
ence between the two rates was considered as 26S proteasomal activity
(chymotrypsin-site).
Statistical analysis
All variables showed normal distribution, when analysed using the
Shapiro–Wilk normality test, and therefore, the parametric statistical
analysis was used. Data were expressed as mean  SEM. Two-way
ANOVA with post hoc testing by Duncan (Statsoft Statistica software
version 8.0; StatSoft, Inc., Tulsa, OK, USA) was used to compare the
effect of genotype (WT and b2KO mice) and surgery (SHAM and MI).
Statistical significance was considered achieved when P < 0.05.
Results
Physiological parameters
Physiological parameters are presented in Table 1. b2-AR disruption
had no impact on either bodyweight or plasma norepinephrine and epi-
nephrine. However, b2KO SHAM displayed reduced heart-to-body-
weight ratio. MI, regardless of genotype, increased heart-to-bodyweight
ratio paralleled by increased plasma norepinephrine and epinephrine
levels. MI extension was similar between WT and b2KO mice.
b2-AR disruption did not alter left ventricle dimensions and con-
tractility while MI induced severe contractile dysfunction (reduced
LVFS) regardless of genotype (Table 2). Of interest, MI induced LV
dilation, at both systole and diastole, which was aggravated by b2-AR
disruption. These data suggest that cardiac remodelling occurs along
with contractile dysfunction in MI groups.
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Myocardial infarction induced plantaris myopathy
and b2-AR disruption aggravates its functional
capacity
Functional capacity was assessed as maximal exercise performance
in running test until exhaustion and ambulation test. Figure 1 shows
that b2KO SHAM mice displayed higher exercise tolerance than WT
SHAM mice (Fig. 1A) with no difference in step-to-body length ratio
(Fig. 1B). Myocardial infarction induced exercise intolerance in both
b2KO MI and WT MI mice when compared with their respective SHAM
control mice; however, the magnitude of distance run reduction was
greater in b2KO than WT MI mice (49  4 versus 30  3%,
P < 0.05; Fig. 1A). Interestingly, only b2KO MI mice displayed
decreased performance on ambulation test (Fig. 1B), which suggests
that b2-AR disruption aggravated MI-induced muscle strength loss.
Fibre type distribution, capillary-to-fibre ratio
and cross-sectional area
In line with the improved exercise tolerance, b2-AR disruption
induced a shift towards type I fibre in plantaris muscle paralleled by
an increased capillary-to-fibre ratio and reduced plantaris type IIB
fibre CSA (Fig. 2A–E).
Myocardial infarction induced a shift towards more glycolytic
fibres (Fig. 2A) and capillary rarefaction (Fig. 2B), however
these responses were more pronounced in b2KO MI mice.
Of interest, reduced plantaris type I, type IIA and type IIB
CSA was restricted to b2KO MI mice, suggesting that lack of
b2-ARs aggravated MI-induced skeletal muscle myopathy
(Fig. 2C–E).
Skeletal muscle expression of proteins involved
in Akt signalling pathway
Figure 3 shows that the expression of proteins involved in Akt sig-
nalling was not affected by genotype, which suggests that the
reduction in type IIB fibres CSA in b2KO SHAM mice was not
related to Akt signalling pathway impairment. In contrast, MI
decreased p-Akt protein levels (Fig. 3B), which was restricted to
b2KO MI mice when compared to WT SHAM mice. No changes
were observed among groups in total 4EBP1, p-4EBP1 at thr70
while an increased p-4EBP1 at thr37/46 was observed in b2KO
SHAM mice compared to WT MI.
Table 1 Physiological parameters
WT b2KO
SHAM (n = 14) MI (n = 11) SHAM (n = 14) MI (n = 12)
Bodyweight (g) 33  1 32  2 33  1 31  1
HW/BW (mg/g) 3.8  0.1 5.8  0.3* 3.0  0.1*,*** 5.2  0.4*,**
LW/BW (mg/g) 5.6  0.1 7.1  0.8* 5.7  0.3 7.8  0.6*,**
Plasma norepinephrine (ng/ml) 7.5  0.7 12.6  1.3* 8.0  0.5*** 10.9  1.3*,**
Plasma epinephrine (ng/ml) 4.6  1.2 16.6  4.1* 6.9  1.0*** 13.1  2.9*,**
Infarcted area (%) – 35  3 – 39  4
Bodyweight, heart weight to bodyweight ratio (HW/BW), lung weight to bodyweight ratio (LW/BW), plasma norepinephrine and epinephrine con-
tent, and infarcted area of WT and b2KO mice submitted to fictitious surgery (SHAM) and myocardial infarction (MI). Data are presented as
mean  SEM. *P < 0.05 versus WT SHAM; **P < 0.05 versus b2KO SHAM; ***P < 0.05 versus WT MI.
Table 2 Echocardiographical data
WT b2KO
SHAM (n = 14) MI (n = 11) SHAM (n = 14) MI (n = 12)
LVFS (%) 48  2 26  2* 45  1*** 22  1*,**
LVESD (mm) 1.65  0.08 3.09  0.13* 1.74  0.06*** 3.72  0.10*,**,***
LVEDD (mm) 3.20  0.12 4.18  0.15* 3.15  0.08*** 4.78  0.12*,**,***
Left ventricular fractional shortening (LVFS), left ventricular end-systolic diameter (LVESD) and left ventricular end-diastolic diameter (LVEDD)
of WT and b2KO mice submitted to fictitious surgery (SHAM) and myocardial infarction (MI). Data are presented as mean  SEM. *P < 0.05
versus WT SHAM; **P < 0.05 versus b2KO SHAM; ***P < 0.05 versus WT MI.
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Fig. 1 Total distance run in graded treadmill running test (A) and step length in ambulation test (B) of WT and b2KO mice submitted to fictitious
surgery (SHAM) and myocardial infarction (MI). Data are presented as mean  SEM. *P < 0.05 versus WT SHAM; #P < 0.05 versus b2KO SHAM;
+P < 0.05 versus WT MI.
A B
C
E
D
Fig. 2 Plantaris muscle fibre type distribution (A) capillary-to-fibre
ratio (B) and cross-sectional area (CSA) of types I, IIA and IIB
fibres (C–E respectively) in WT and b2KO mice submitted to ficti-
tious surgery (SHAM) and myocardial infarction (MI). Data are
presented as mean  SEM. *P < 0.05 versus WT SHAM;
#P < 0.05 versus b2KO SHAM; +P < 0.05 versus WT MI.
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1091
J. Cell. Mol. Med. Vol 18, No 6, 2014
A B
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E
D
Fig. 3 Plantaris expression of Protein Kinase B (Akt1, A), Protein
Kinase B phosphorylated at ser473 (p-Akt ser473, B), Eukaryotic
translation initiation factor 4E-binding protein 1 (4E-BP1, C), Eukary-
otic translation initiation factor 4E-binding protein 1 phosphorylated
at thr70 (p-4E-BP1 thr70, D), Eukaryotic translation initiation factor
4E-binding protein 1 phosphorylated at thr37/46 (p-4E-BP1 thr37/
46, E) in WT and b2KO mice submitted to fictitious surgery (SHAM)
and myocardial infarction (MI). Data are presented as mean  SEM
after normalization against Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). *P < 0.05 versus WT SHAM; #P < 0.05 versus
b2KO SHAM; +P < 0.05 versus WT MI.
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Skeletal muscle ubiquitin–proteasome system
Lack of b2-ARs had no impact on FoxO3a, p-FoxO3a, Atrogin-1,
MuRF1 protein expression and protein ubiquitination (Fig. 4A–E),
whereas it decreased chymotrypsin-like proteasome activity
(Fig. 4F).
Myocardial infarction increased Atrogin-1 protein expression in
both WT and b2KO mice (Fig. 4C). Additionally, a significant
increased MuRF1 expression was observed in b2KO MI compared
with WT SHAM (Fig. 4D). Figure 4E shows that MI increased protein
ubiquitination, a master signal for proteasomal degradation, was
restricted to b2KO MI mice and accompanied by an increased chymo-
trypsin-like proteasome activity (Fig. 4F).
Discussion
Here, we report for the first time that lack of b2-ARs aggravates HF-
induced skeletal myopathy in infarcted mice. The main findings of the
present study are that MI associated with b2-AR gene targeting dis-
ruption induces: (i) more pronounced exercise intolerance when com-
pared with WT MI group, (ii) skeletal muscle atrophy paralleled by
decreased p-Akt protein levels and increased expression of proteins
involved in UPS.
Exercise tolerance is a clinical predictor of HF syndrome and it
is closely related to cardiac and skeletal muscle function [3, 20].
Presently, a greater reduction in functional capacity was observed
in b2KO MI than WT MI mice when both running until exhaustion
and ambulation tests were assessed. b2-AR gene inactivation had
no additional impact on MI-induced impaired left ventricle contrac-
tility while it aggravated plantaris myopathy. Even though the
greater reduction in functional capacity of b2KO MI mice seems to
rely on skeletal muscle abnormalities in the absence of b2-ARs,
we cannot exclude that a minor reduction in cardiac output could
also affect exercise tolerance. However, it is important to highlight
that symptoms that typify HF, such as degree of exercise intoler-
ance, are not directly related to the degree of cardiac dysfunction
[3–5] but directly related to abnormalities in skeletal muscle and
we presently extended this knowledge to the role of b2-AR signal-
ling in this process. Indeed, we cannot exclude the possibility that
part of this greater decrease in exercise tolerance of b2KO MI
mice could be related to the reversal of the skeletal muscle adap-
tations underlying the higher baseline exercise tolerance observed
in b2KO SHAM mice (e.g. greater soleus and plantaris percentage
of oxidative fibres, capillarization, glycogen content and activity of
oxidative enzymes) [10].
Chronic sympathetic hyperactivity is detrimental and might
reduce b2-AR signalling in skeletal muscle contributing to installa-
tion of skeletal myopathy. In fact, we have observed reduction in
b2-AR protein levels in WT MI when compared with WT SHAM
mice (Figure S1) associated with increased norepinephrine and epi-
nephrine plasma levels (Table 1), which suggests that a reduced
b2-AR signalling might precede the installation of HF-induced
myopathy. This is of particular importance as b2-ARs are highly
expressed (a ~10-fold greater proportion than either b1 or b3 ARs)
in skeletal muscle and regulate muscle contraction, metabolism and
mass [21]. In line with these findings, b2-AR gene inactivation
aggravated MI-induced plantaris myopathy in b2KO MI character-
ized by a more pronounced reduction in type I fibres and capillar-
ity, and mainly skeletal muscle atrophy when compared with WT
MI mice.
As b2-AR activation leads to skeletal muscle hypertrophy [7,
8], its absence in a catabolic condition, such as HF, might have
contributed for the induction of skeletal muscle atrophy observed
in b2KO MI mice. In fact, the anabolic and anti-catabolic effects of
b2-AR activation have been explained by its impact on the balance
between protein synthesis and degradation. b2-AR by coupling to
Gai subunit and/or by activating cAMP/Epac pathway can further
activate downstream pathways, such as Akt signalling that, when
phosphorylated, increases protein synthesis while reduces protein
degradation by UPS in skeletal muscle [8, 22–24]. Accordingly, we
presently observed that b2-AR disruption and MI were paralleled
by a reduction in phosphorylated Akt protein levels (p-Akt ser 473,
Fig. 3B) and activation of UPS (Fig. 4C–F) in plantaris muscle of
b2KO MI mice. Thus, reduced p-Akt might be a mechanistic link
between reduced b2-AR signalling and skeletal muscle atrophy
in HF.
Akt activation leads to an increased protein synthesis through
mTOR signalling or reduction in protein degradation through FoxO
inhibition, which decreases atrogenes transcription, such as atrogin-1
and MuRF1 [25, 26]. As we have observed no difference in 4EBP1
and p-4EBP1 protein levels, the skeletal muscle atrophy in b2KO MI
mice does not seem to be modulated by an impaired protein synthe-
sis. In contrast, decreased p-Akt protein levels observed in b2KO MI
mice were paralleled by increased protein levels of atrogin-1, MuRF1
and ubiquitinated proteins, as well as by increased chymotrypsin-like
proteasome activity. These data support an association between
decreased p-Akt protein levels and the increased UPS activation in
b2KO MI mice that could be mediated by FoxO transcription factors,
as FoxO phosphorylation by Akt inhibits FoxO induction of atrogin-1
and MuRF1 transcription [25, 26]. Even though we have not observed
a significant decrease in phosphorylated FoxO3a protein levels (main
isoform involved in skeletal muscle atrophy) in plantaris of b2KO MI
mice, we cannot exclude that other FoxO isoforms could be involved
in these responses. In fact, both FoxO1 and FoxO4 have also been
implicated in the regulation of atrogin-1 and MuRF1 in catabolic pro-
cesses [27–29]. Moreover, we cannot exclude that the greater
decrease in phosphorylated FoxO3a in b2KO MI mice might have
occurred prior to the stage of HF presently studied (90 days after
MI).
The crucial role of UPS in HF-induced skeletal muscle atrophy
observed in the present study corroborates our previous findings [30,
31] and others [32–34]. In fact, UPS is considered the main proteo-
lytic system involved in skeletal muscle atrophy [35, 36], as it is
responsible for cleaving about 90% of cytosolic proteins [37].
Altogether, our results give support to the notion that b2-AR dis-
ruption accelerates the installation of skeletal muscle atrophy in MI-
induced HF. Considering that skeletal muscle atrophy and cachexia
are related to poor prognosis and mortality in HF [38], it is relevant to
drive more attention to skeletal myopathy in HF pharmacological
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Fig. 4 Plantaris expression of Forkhead Box O3 (FoxO3a, A), Forkhead
Box O3 phosphorylated at ser253 (p-FoxO3a ser253, B), F-box protein
32 (Atrogin-1, C), Muscle RING-finger protein-1 (MuRF1, D), protein
ubiquitination (E) and 26S proteasome activity (F) in WT and b2KO mice
submitted to fictitious surgery (SHAM) and myocardial infarction (MI).
Data are presented as mean  SEM after normalization against Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH). *P < 0.05 versus WT
SHAM; #P < 0.05 versus b2KO SHAM; +P < 0.05 versus WT MI.
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therapy, particularly to b-blockers therapy, which is normally directed
at improving cardiac function and do not counteract exercise intoler-
ance or skeletal myopathy [6, 39–41]. Even though the use of
non-selective b-blockers with antioxidant and vasodilatory effects
have impact on counteracting some features of HF-induced skeletal
myopathy [42], the use of b1-AR selective b-blockers (cardiac action
with minimal effect on skeletal muscle) with vasodilatory and antioxi-
dant properties could have even higher effect counteracting skeletal
myopathy considering that preserved b2-AR signalling could potenti-
ate these peripheral effects. In fact, nebivolol has been shown to be
effective with greater benefits than prior generations of b-blockers
[43–45]. However, further studies are required to better understand
the effect of different b-blockers normally used for HF therapy on
skeletal myopathy.
Study limitations
One might argue that the aggravated skeletal myopathy in b2KO mice
could be related to a greater decrease in cardiac output in the absence
of cardiac b2-ARs. Even though b2-AR gene inactivation had no
impact on MI-induced impaired left ventricle FS and increased plasma
norepinephrine and epinephrine levels, we cannot exclude that a
minor decrease in cardiac output associated with greater left ventricle
dimensions might have contributed to skeletal myopathy observed in
b2KO mice.
Even though b2-AR is the predominant b-AR isoform expressed in
skeletal muscle, one might suggest that, in the absence of b2-AR
protein expression, up-regulation of b1-ARs could affect our results.
This seems not be the case, since b2-AR gene inactivation did not
alter plantaris b1-AR protein levels in both SHAM and MI groups
(Figure S2).
In the present study, we focused on the skeletal muscle b2-AR
signalling controlling skeletal muscle mass to better understand
its role in HF-induced skeletal myopathy. However, b2-ARs are
also expressed in vessels and its activation induces smooth mus-
cle relaxation and endothelium-derived nitric oxide release [46,
47]. However, b1-AR is the main b-AR subtype involved in vasodi-
lation of resistance vessels (femoral artery and vein) [48] while
both b1- and b2-ARs [48, 49] are involved in mediating vasodila-
tion in conductance arteries (thoracic aorta). Of interest, we previ-
ously reported similar b1-AR immunostaining in aorta of WT and
b2KO mice [49]. Therefore, if b2-AR gene inactivation leads to
changes in vessel smooth muscle tone, these changes would be
negligible.
Conclusion and perspective
Taken together, we provide evidence that inactivation of b2-AR aggra-
vates MI-induced plantaris myopathy and anticipates plantaris atro-
phy associated with increased UPS activation. Altogether, we provide
new insights on the molecular mechanisms whereby b2-AR can coun-
teract skeletal myopathy in HF, which should be taken into consider-
ation for the use of selective versus non-selective b-AR subtype
antagonist therapy in HF.
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